knowledge -WSS

knowledge

author：comprehensive 2025-10-01 00:58:01 - browse：21

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

The Food and Drug Administration granted conditional approval Thursday to the first gene therapy for Duchenne muscular dystrophy. Regulators restricted the treatment to younger patients, with additional data required to broaden its use.

The gene therapy, called Elevydis, is made by Sarepta Therapeutics. The company will charge $3.2 million for the treatment, making it the U.S.’s second most expensive drug, behind a recently approved gene therapy for hemophilia. CEO Doug Ingram said on a conference call the price was below what a recently published company-funded analysis found would be cost-effective.

“The approval of Elevidys is a watershed moment for the treatment of Duchenne. Elevydis is the first and only gene therapy approved for Duchenne, and this approval brings us closer to our goal of bringing forward a treatment that provides the potential to alter the trajectory of this degenerative disease,” Ingram said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Albert Bourla of Pfizer: worst biopharma CEO of 2023

entertainment

knowledge

WSS

What STAT readers think about the FDA and patient advocacy

Violet CEO on training clinicians to promote more inclusive care

Medicare drug price negotiation hasn't dried up venture capital

SEC charges former device maker CEO with $41 million fraud

Grail spinoff by Illumina should end disastrous merger attempt

340B reform proposal comes out of Senate working group

hotspot

knowledge

entertainment

The high cost of giving birth even with insurance

Why Novartis is going to walk from its acquisition of MorphoSys

The cancer drug shortage isn’t new — and neither are the solutions

Why Novartis is going to walk from its acquisition of MorphoSys

Cancer drug shortages should be causing more outrage

Editas, Vertex strike deal on CRISPR

Wildfire smoke exposes gaps in outdoor worker protections

Devoted Health’s losses in Medicare Advantage persist

Peter Hotez and the public health issue of online harassment

Why health records don't always know when patients are dead

explore

Drinking less cuts risk of oral cavity, esophageal cancer: Report

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

Problems with a popular proposal to regulate AI in health care

Global cancer cases to surge 77% by 2050, WHO report says

What STAT readers think about the FDA and patient advocacy

Medicare drug price negotiation hasn't dried up venture capital

entertainment

knowledge

hotspot

entertainment